Results 261 to 270 of about 8,290,554 (306)
Some of the next articles are maybe not open access.
Pharmacoeconomics of Biologic Therapy
Immunology and Allergy Clinics of North America, 2017Novel biologic agents have allowed clinicians to achieve improved patient outcomes. Appropriate pharmacoceconomic analyses demand evaluation of all relevant costs, including the treatments, the disease and comorbidities, and costs of alternative treatments, including their short- and long-term side effects.
Don A, Bukstein, Allan T, Luskin
openaire +2 more sources
Biological therapy for psoriasis
British Journal of Hospital Medicine, 2006Psoriasis is a common, chronic immune-mediated skin disorder. Recent advances in the understanding of the immunopathogenesis of psoriasis have led to the development of biological agents designed to target the molecular mechanisms of the condition. These provide new and effective treatments for patients with moderate to severe psoriasis.
Suzanne E, Clements +2 more
openaire +2 more sources
Biologic therapies in dermatology
British Journal of Hospital Medicine, 2013Biologic therapies, the anti-cytokines in particular, have proved to be a significant addition to the dermatologist’s armamentarium for the management of severe skin disease. This article summarizes the mechanism of action, dosage, approved indications, off-label uses and the future of biologic therapies in dermatology.
Chularojanamontri, Leena +1 more
openaire +4 more sources
Journal of Crohn's & Colitis, 2020
BACKGROUNDS AND AIMS Fatigue is prevalent in patients with inflammatory bowel diseases (IBD). Biologic therapy is effective in achieving symptomatic and endoscopic remission, but its impact on fatigue is less well established.
Nienke Z. Borren +7 more
semanticscholar +1 more source
BACKGROUNDS AND AIMS Fatigue is prevalent in patients with inflammatory bowel diseases (IBD). Biologic therapy is effective in achieving symptomatic and endoscopic remission, but its impact on fatigue is less well established.
Nienke Z. Borren +7 more
semanticscholar +1 more source
The Immunogenicity of Biologic Therapies
2017Virtually all therapeutic proteins (biologics) elicit an immune response with the consequent production of anti-drug antibodies (ADA). The majority of ADA to therapeutic monoclonal antibodies (mAbs) are directed against the antigen-binding site of the therapeutic mAb, and hence are neutralizing.
Sandra, Garcês, Jocelyne, Demengeot
openaire +2 more sources
Clinical Gastroenterology and Hepatology, 2021
BACKGROUND AND AIMS We conducted a systematic review and meta-analysis to summarize emerging data on the safety and effectiveness of dual biologic therapy in combination or with tofacitinib in patients with refractory inflammatory bowel disease (IBD ...
Waseem Ahmed +7 more
semanticscholar +1 more source
BACKGROUND AND AIMS We conducted a systematic review and meta-analysis to summarize emerging data on the safety and effectiveness of dual biologic therapy in combination or with tofacitinib in patients with refractory inflammatory bowel disease (IBD ...
Waseem Ahmed +7 more
semanticscholar +1 more source
Current Opinion in Oncology, 1999
Biologic approaches to lymphoma treatment are now a practical reality rather than a vaguely perceived hope for the future. Interferon alfa seems to have been established as a life-extending therapy for selected patients with follicular lymphoma. Humanized anti-CD20 monoclonal antibody (rituximab) has an authentic 50% response rate in patients with ...
M, Bendandi, D L, Longo
openaire +2 more sources
Biologic approaches to lymphoma treatment are now a practical reality rather than a vaguely perceived hope for the future. Interferon alfa seems to have been established as a life-extending therapy for selected patients with follicular lymphoma. Humanized anti-CD20 monoclonal antibody (rituximab) has an authentic 50% response rate in patients with ...
M, Bendandi, D L, Longo
openaire +2 more sources
Seminars in Arthritis & Rheumatism, 2020
PURPOSE We assessed the efficacy and safety of biologic therapy in severe and refractory Peripheral Ulcerative Keratitis (PUK). DESIGN Open-label multicenter study of biologic-treated patients with severe PUK refractory to conventional ...
L. Domínguez-Casas +18 more
semanticscholar +1 more source
PURPOSE We assessed the efficacy and safety of biologic therapy in severe and refractory Peripheral Ulcerative Keratitis (PUK). DESIGN Open-label multicenter study of biologic-treated patients with severe PUK refractory to conventional ...
L. Domínguez-Casas +18 more
semanticscholar +1 more source
The Future of Biological Therapies
Seminars in Cutaneous Medicine and Surgery, 2010The last decade has witnessed a significant advance in the management of refractory moderate-to-severe psoriasis. This advance is the introduction of biological therapies to clinical practice. Three classes of biological therapies have been used. Of the first 2 classes to be introduced, the T-cell inhibitors and tumor necrosis factor (TNF)-alpha ...
Warren, Richard B. +1 more
openaire +3 more sources
American Journal of Gastroenterology, 2020
INTRODUCTION De-escalation of biologic therapy is a commonly encountered clinical scenario. Although biologic discontinuation has been associated with high rates of relapse, the effectiveness of dose de-escalation is unclear. This review was performed to
Derek H. W. Little +5 more
semanticscholar +1 more source
INTRODUCTION De-escalation of biologic therapy is a commonly encountered clinical scenario. Although biologic discontinuation has been associated with high rates of relapse, the effectiveness of dose de-escalation is unclear. This review was performed to
Derek H. W. Little +5 more
semanticscholar +1 more source